News & Updates | The Sage Group

Sage Group News

Zhimeng Biopharma Announces Global Partner Search for its' Development of Chronic Hepatitis B Cure

Shanghai, China and New York, USA, 1 March 2021 – Following a strategic review of its clinical and commercial development options,...

The Sage Group Announces $100M+ Transaction between medac GmbH and Medexus Pharma for Trecondi

The Sage Group Inc. served as exclusive advisor to medac GmbH on this $100M+ transaction. Medexus Pharmaceuticals and medac GmbH enter...

Squarex Announces End of Phase 2 Meeting with FDA for its Cold Sore Prevention Asset

Saint Paul, Minnesota, USA, 19 January 2021 – Squarex Pharma (SQX), a St. Paul, Minnesota, USA-based company, announced updated results...

Exhalation Technology Announces Updated Clinical Trial Data for its Rapid Covid-19 Diagnostic Test

Cambridge, England, 4 January 2021 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced updated results from its...

Exhalation Technology Launch Clinical Trial for CoronaCheck™ – A Rapid Covid-19 Diagnostic Test

Cambridge, England, 2 November 2020 – Exhalation Technology (ETL), a Cambridge, UK-based company, announced the start of a large clinical...

Exhalation Technology Announces Search for Partners for its Covid-19 Rapid Diagnostic Test

Cambridge, England, 24 September 2020 – Exhalation Technology has appointed The Sage Group to lead the partnering program for its novel...

Sage Represents Respira Therapeutics - Opportunity to License RT234, A Late Stage Asset for Pulmonar

The Sage Group is working with Respira Therapeutics (“Respira”; http://respiratherapeutics.com/) to identify clinical and commercial...

Sage Represents DBM: An Opportunity to Acquire or Partner with a Revenue Generating Pre-Clinical CRO

The Sage Group is pleased to announce it is representing Discovery Biomed (“DBM”; https://discoverybiomed.com/). DBM is a...